A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Last updated: April 18, 2024
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurofibromatosis

Brain Tumor

Warts

Treatment

This study is purely descriptive study.

Clinical Study ID

NCT06379230
SH9H-2023-T378-1
  • All Genders

Study Summary

Background/Rationale: Neurofibromatosis type 1 (NF1) affects about 1 in every 3000 people worldwide. Globally, 30~50% NF1 patients will develop plexiform neurofibromas (PNs), which grow rapidly in early childhood and can cause disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder and bowel dysfunction. This systemic disease imposes a heavy psychosomatic and financial burden on patients and their caregivers. In NF1 patients, the lifetime risk of MPNST developed from PN is 8% to 13%. The mean age for NF1-associated death was approximately 20 years lower than that for the general population. Limited epidemiological and clinical data of Chinese NF1 patients is available to date. And the treatment pattern of Chinese NF1-PN patients is also unknown.

Objectives and Hypotheses: It is a descriptive study without formal hypothesis. The primary objective of this study is determining the percentage of NF1 patients who develop PN. The secondary objectives of this study include describing the clinical characteristics, tumor progression and treatment pattern of NF1-PN. The exploratory objective is exploring the epidemiological characteristics of other NF1 manifestations.

Methods:

Study design: The study is a retrospective multi-center chart review study. Data Source(s): All the data will be collected by CRF from inpatient and outpatient electronic medical records in every study site from January 1, 2019 to December 31, 2022.

Study Population: Patients who attended the study sites between January 1, 2019 - December 31, 2022 and were diagnosed with NF1 were included in this study. Statistical Analysis: This study is purely descriptive without any formal hypotheses.

Missing data for baseline characteristics will be assessed and addressed as a categorical variable with a level for missingness. All reported measures will be summarized in the study tables. Point estimates and their 95% CIs will be presented in the final analyses.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients who attended the study sites between January 1, 2019, and December 31, 2022.
  2. Patients who were diagnosed with NF1(recorded with the text of type Ineurofibromatosis) based on National Institutes of Health (NIH) NF1 consensus.

Exclusion

Exclusion Criteria:

  1. Patients combined with other malignant tumors

Study Design

Total Participants: 2000
Treatment Group(s): 1
Primary Treatment: This study is purely descriptive study.
Phase:
Study Start date:
January 01, 2019
Estimated Completion Date:
February 28, 2025

Connect with a study center

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing
    China

    Active - Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi
    China

    Active - Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan
    China

    Active - Recruiting

  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai 200011
    China

    Site Not Available

  • West China Hospital, Sichuan University

    Chengdu, Sichuan
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.